Far from energizing the ‘march-in’ debate, the GAO study finds limited potential impact, but a new antitrust clause in licensing agreements could give companies something to worry about even if specter of government pricing setting might not be a big concern. Even though GAO found that NIH-licensed products amount to about 1% of government drug spend, the issue isn’t likely to disappear because Biden will face continued pressure to act on drug pricing and a Republican Senate gives him few options.

Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.

The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.